Such insights could facilitate the development of novel interventions targeting TLR4-mediated neuroinflammatory pathways in diseases such as Alzheimer’s disease, multiple sclerosis, and Parkinson’s disease. This evidence concerns the gene TLR4 and early-onset autosomal dominant Alzheimer disease.